Judge Richard G. Andrews of the US District Court, District of Delaware, has found that Lannett has infringed on the US patents 6,750,237 and 7,220,767 related to Zomig zolmitriptan nasal spray, Impax Laboratories has announced.
In 2014, Impax filed suit against Lannett after Lannett filed an ANDA for a generic version of Zomig nasal spray.
In 2012, Impax acquired US rights to Zomig nasal spray from AstraZeneca, which is also a plaintiff in the case. The judge will allow Lannett to argue that AstraZeneca does not have standing in the case, and the ruling is subject to appeal.
Impax President and CEO Paul Bisaro commented, “We are pleased with the court’s decision upholding the validity of the patents for Zomig nasal spray. We look forward to continuing to supply this product to patients and will continue to actively protect our intellectual property.”
Read the Impax Laboratories press release.
